Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO 140 (Leronlimab) extension study in HIV-1
NCT02990858Phase 3Terminated
- Sponsor
- CytoDyn Inc.
- Start
- Nov 2016
- Primary completion
- Jun 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
01
Overview
A Phase 3 trial of leronlimab in human immunodeficiency virus infection (HIV), sponsored by CytoDyn Inc.. Started Nov 2016; status: terminated.
02
Drugs
leronlimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02990858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02990858.